Okay, interesting. But am I confused here? I thought Auryxia is a phosphate binder... the iron improvement was a secondary benefit. So would that only hinder Auryxia sales for off-label prescriptions? And if someone taking it for use as a phosphate binder, then if they receive the secondary benefits, they would not need this other drug. If the patient simply has anemia and does not need a phosphate binder, then this drug would be more useful to them. I am far from an expert on kidney disease or how it is treated. Correct me if I am wrong.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.